Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

Aims Modifications of antimicrobials’ pharmacokinetic parameters have been reported in critically ill patients, resulting in a risk of treatment failure. We characterized amikacin pharmacokinetic variability in critically ill patients with ventilator-associated pneumonia (VAP) and evaluated several dosing regimens.